Literature DB >> 20219378

Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia.

Markus K Dahlgren1, Caroline E Zetterström, Sa Gylfe, Anna Linusson, Mikael Elofsson.   

Abstract

A combined application of statistical molecular design (SMD), quantitative structure-activity relationship (QSAR) modeling and prediction of new active compounds was effectively used to develop salicylidene acylhydrazides as inhibitors of type III secretion (T3S) in the Gram-negative pathogen Yersinia pseudotuberculosis. SMD and subsequent synthesis furnished 50 salicylidene acylhydrazides in high purity. Based on data from biological evaluation in T3S linked assays 18 compounds were classified as active and 25 compounds showed a dose-dependent inhibition. The 25 compounds were used to compute two multivariate QSAR models and two multivariate discriminant analysis models were computed from both active and inactive compounds. Three of the models were used to predict 4416 virtual compounds in consensus and eight new compounds were selected as an external test set. Synthesis and biological evaluation of the test set in Y. pseudotuberculosis and the intracellular pathogen Chlamydia trachomatis validated the models. Y. pseudotuberculosis and C. trachomatis cell-based infection models showed that compounds identified in this study are selective and non-toxic inhibitors of T3S dependent virulence. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219378     DOI: 10.1016/j.bmc.2010.02.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

1.  Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Authors:  Anatoly Slepenkin; Hencelyn Chu; Mikael Elofsson; Pia Keyser; Ellena M Peterson
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

Review 2.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

3.  In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds.

Authors:  Donald N Forthal; Tran B Phan; Anatoly V Slepenkin; Gary Landucci; Hencelyn Chu; Mikael Elofsson; Ellena Peterson
Journal:  Int J Antimicrob Agents       Date:  2012-07-20       Impact factor: 5.283

4.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

5.  Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.

Authors:  Patrik Engström; Bidong D Nguyen; Johan Normark; Ingela Nilsson; Robert J Bastidas; Asa Gylfe; Mikael Elofsson; Kenneth A Fields; Raphael H Valdivia; Hans Wolf-Watz; Sven Bergström
Journal:  J Bacteriol       Date:  2013-07-12       Impact factor: 3.490

6.  Mixed learning algorithms and features ensemble in hepatotoxicity prediction.

Authors:  Chin Yee Liew; Yen Ching Lim; Chun Wei Yap
Journal:  J Comput Aided Mol Des       Date:  2011-09-06       Impact factor: 3.686

7.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

8.  Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner.

Authors:  Xiaofeng Bao; Asa Gylfe; Gail L Sturdevant; Zheng Gong; Shuang Xu; Harlan D Caldwell; Mikael Elofsson; Huizhou Fan
Journal:  J Bacteriol       Date:  2014-06-09       Impact factor: 3.490

9.  Small molecules aimed at type III secretion systems to inhibit bacterial virulence.

Authors:  Lun K Tsou; Paul D Dossa; Howard C Hang
Journal:  Medchemcomm       Date:  2013-01-01       Impact factor: 3.597

10.  Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion.

Authors:  Tofeeq Ur-Rehman; Anatoly Slepenkin; Hencelyn Chu; Anders Blomgren; Markus K Dahlgren; Caroline E Zetterström; Ellena M Peterson; Mikael Elofsson; Asa Gylfe
Journal:  J Antibiot (Tokyo)       Date:  2012-06-06       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.